Bone News and Research

RSS

Update on new clinical developments and other initiatives related to Ceplene

EpiCept Corporation today provided an update on new clinical developments and other initiatives related to Ceplene® (histamine dihydrochloride), the Company’s therapy approved in the European Union for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.

15 Dec 2009

ProChon Biotech announces expansion of BioCart Cartilage Regeneration System study

ProChon Biotech, Ltd., an innovator of tissue regenerative technologies that are being developed to relieve pain and restore the mobility and quality of life for sufferers of articular cartilage injuries, today announced a significant expansion of its clinical study of the BioCart™ Cartilage Regeneration System.

15 Dec 2009

New program to help maintain bone health in men with prostate cancer on ADT announced

Watson Pharmaceuticals, Inc. today announced a new program encouraging health professionals to help maintain the bone health of prostate cancer patients who are on long-term androgen deprivation therapy (ADT).

15 Dec 2009

Protozoan parasite may be the cause for dinosaur extinction

Infectious diseases can be transmitted by sneezing, touching, or - for Tasmanian devils - biting each other on the face, a habit that may have driven the dinosaurs to extinction through the transmission of a protozoan parasite.

15 Dec 2009

SBi secures $30mm credit facility to fund business expansion

Small Bone Innovations, Inc. (SBi), a leading, privately held orthopedics company focused exclusively on technologies and treatments for the small bones & joints, has closed on a $30mm credit facility to fund accelerated business expansion and refinance existing indebtedness.

15 Dec 2009

UT Southwestern Medical Center performs minimally invasive procedures for sinuses and chronic rhinosinusitis

Only about one in 2,000 people in the United States get a sinus tumor, but Johnnie Wilcox was one of the unfortunate few.

15 Dec 2009

NAMS recommends women to discuss osteoporosis with their OB/GYNs

According to a new survey distributed by The North American Menopause Society (NAMS), while 98 percent of women who participated consider bone strength to be an important health concern, nearly half (45 percent) of these women reported that osteoporosis was not addressed during their last routine OB/GYN visit, and more than a quarter (26.4 percent) of women surveyed have never discussed osteoporosis with their OB/GYN.

14 Dec 2009

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.

14 Dec 2009

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Algeta ASA, the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton.

14 Dec 2009

NICE guidelines limit options for low cost osteoporosis drugs

Low cost osteoporosis drugs are strictly rationed for the under 75s, and UK physicians hampered by restrictive guidelines, according to findings which appear today in the journal Therapeutic Advances in Musculoskeletal Disease, published by SAGE.

14 Dec 2009

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.

14 Dec 2009

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

A modified blood adult stem-cell transplant regimen has effectively reversed sickle cell disease in 9 of 10 adults who had been severely affected by the disease, according to results of a National Institutes of Health study in the Dec. 10 issue of the New England Journal of Medicine.

13 Dec 2009

Zevalin clinical data presented at 2009 ASH meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN (ibritumomab tiuxetan) was presented at the 51st Annual Meeting of the American Society of Hematology (ASH), which was held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

11 Dec 2009

Pfizer announces IES analysis of Aromasin in breast cancer recurrence

Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.

11 Dec 2009

NAA protests against abusive restraint and seclusion in schools

Today the National Autism Association announced its support of H.R. 4247, the Preventing Harmful Restraint and Seclusion in Schools Act, introduced Wednesday by Congressman George Miller (D-CA) and Congresswoman Cathy McMorris Rodgers (R-WA). The federal bill is a much-anticipated solution to the issues of unregulated restraint and seclusion in schools.

11 Dec 2009

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Bisphosphonates are routinely given to women with postmenopausal breast cancer, but new data suggests that these agents may play a role in reducing recurrent breast cancer as well.

11 Dec 2009

New vehicle headrest to prevent whiplash injuries

Whiplash neck injuries among drivers and their passengers who have been shunted from behind are a major cause of long-term health problems and, in extreme cases, death.

11 Dec 2009

Genentech and Biogen Idec report positive outcome from ocrelizumab-MTX combination study in RA

Genentech, Inc. a wholly owned member of the Roche Group, and Biogen Idec announced today a Phase III study (STAGE) of the investigational humanized anti-CD20 monoclonal antibody ocrelizumab given in combination with methotrexate (MTX) met its primary endpoint of improving signs and symptoms (as measured by American College of Rheumatology or ACR20 response) in rheumatoid arthritis (RA) patients who had an inadequate response to MTX at both 24 and 48 weeks.

11 Dec 2009

Stem cell therapy can be used for LSCD, reports newly published research

Newly published research, by investigators, at the North East England Stem Cell Institute (NESCI) in the journal Stem Cells reported the first successful treatment of eight patients with "Limbal Stem Cell Deficiency" (LSCD) using the patients' own stem cells without the need of suppressing their immunity.

11 Dec 2009

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

Bone News and Research

Update on new clinical developments and other initiatives related to Ceplene

ProChon Biotech announces expansion of BioCart Cartilage Regeneration System study

New program to help maintain bone health in men with prostate cancer on ADT announced

Protozoan parasite may be the cause for dinosaur extinction

SBi secures $30mm credit facility to fund business expansion

UT Southwestern Medical Center performs minimally invasive procedures for sinuses and chronic rhinosinusitis

NAMS recommends women to discuss osteoporosis with their OB/GYNs

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

NICE guidelines limit options for low cost osteoporosis drugs

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

Zevalin clinical data presented at 2009 ASH meeting

Pfizer announces IES analysis of Aromasin in breast cancer recurrence

NAA protests against abusive restraint and seclusion in schools

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

New vehicle headrest to prevent whiplash injuries

Genentech and Biogen Idec report positive outcome from ocrelizumab-MTX combination study in RA

Stem cell therapy can be used for LSCD, reports newly published research

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News